Aflibercept as a Second Line Therapy for Neovascular Age Related Macular Degeneration in Israel (ASLI) study. [electronic resource]
Producer: 20171211Description: 890-898 p. digitalISSN:- 1476-5454
- Aged
- Angiogenesis Inhibitors -- administration & dosage
- Bevacizumab -- administration & dosage
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Substitution
- Female
- Follow-Up Studies
- Humans
- Intravitreal Injections
- Israel -- epidemiology
- Macula Lutea -- pathology
- Male
- Prevalence
- Prospective Studies
- Receptors, Vascular Endothelial Growth Factor -- administration & dosage
- Recombinant Fusion Proteins -- administration & dosage
- Tomography, Optical Coherence
- Treatment Outcome
- Visual Acuity
- Wet Macular Degeneration -- diagnosis
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.